Drug intelligence / Profile preview

AD-214-02

Development stage: Phase 1
Lead developer: AdAlta
Modality: Small Molecules
Administration: Oral

Overview

AD-214-02 is a drug developed by Addpharma Inc. It is currently being investigated in a Phase 1 clinical trial (NCT04622358) to assess its safety, pharmacokinetics, and pharmacodynamics. The study compares AD-214-02 to Rabeprazole in healthy volunteers. It is administered orally as a tablet. The specific mechanism of action and primary therapeutic indication for AD-214-02 are not disclosed in the provided context.

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on AD-214-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-214-02.